Referenzen:

1. Widemann BC et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcomes. J Clin Oncol. 2010;28(25):3979-3986.

2. Howard SC et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471-1482.

3. Voraxaze^® 1000 Einheiten Pulver zur Herstellung einer Injektionslösung Fachinformation, Stand Februar 2024.